Osivax is a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses.
About
Osivax is a clinical-stage biotech company leveraging platform technology, oligoDOM™, to transform the respiratory virus vaccine landscape with pan-flu and pan-covid-19 vaccines delivered in one single shot. The company is establishing proof of concept with its broad-spectrum “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trial with over 1,200 participants and encouraging Proof of Concept efficacy in human.